Movement Alert｜Twist Bioscience Corp Intraday Decline 5.58%, earnings preview and prior AI drug discovery catalysts remain under digestion

Market Focus11-05 22:40

On November 5, Twist Bioscience Corp fell 5.58% in Regular Trading, trading at $128.85/share, with turnover of $15.45 million.

The latest market narrative points to a pre-earnings digestion phase rather than a fresh standalone catalyst. The company is scheduled to report on November 12, with consensus expecting revenue of about $123 million, up 25.96% year over year, adjusted EPS of about -$0.37 to -$0.44, and a continued narrowing in losses.

Recent background factors being digested by the market include expectations tied to a large AI drug discovery order, collaboration with Eli Lilly's TuneLab to provide antibody characterization data services, and newly initiated bank coverage carrying Hold or Neutral views with price targets around $144 to $150. The combination has kept trading interest elevated, but recent reports indicate no materially stronger new catalyst has emerged, contributing to sharper short-term volatility.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment